Project Grant R44CA180745

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,811,052 to Manzanita Pharmaceuticals Inc. to conduct IND-enabling toxicology and safety studies for a novel nerve imaging agent called "NERVELIGHT" for use during radical prostatectomy procedures. NERVELIGHT is comprised of a near-infrared dye attached to recombinant human nerve growth factor (rhNGF) that selectively binds to nerve tissue, allowing...

Renerva LLC, a for-profit manufacturer, is developing peripheral nerve matrix (PNM) technologies to facilitate functional recovery in animal models of direct muscle neurotization (DMN) through a $494,955 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The two-year project aims to 1) optimize the formulation of a clinical-grade PNM product to provide...

This $381,100 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development and evaluation of tumor-targeting polymeric micelles carrying a near-infrared (NIR) imaging agent. The goal is to provide optical image guidance during brain cancer surgery to improve tumor resection and surgical outcomes. The key products to be delivered under this 4-year grant (7/15/2024 - 6/30/2028)...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, will support the development of a new multi-spectral light source called the "Effective Uniform Color-Light Integration Device (EUCLID)" for biological imaging applications. The $293,588 award will be used to create two different EUCLID designs - one that uses commercial LED bulbs for oblique excitation light to monitor neuronal activity, and...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $999,998.00 to Renerva LLC, a Pittsburgh-based biomedical technology company, to optimize a proprietary Peripheral Nerve Matrix (PNM) formulation derived from porcine nerve tissue. The goal is to develop an improved nerve conduit filler that can exceed the performance of...

The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, awarded a $296,151 Project Grant to Insoma Bio, Inc. to investigate the use of the company's proprietary Fractomer biomaterial to improve outcomes after peripheral nerve repair. The funding will support research to tailor the Fractomer formulation for peripheral nerve applications and evaluate its...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,522,833 Project Grant to The Leland Stanford Junior University to conduct a mechanistic randomized clinical trial investigating the central and peripheral nervous system mechanisms of pain relief induced by peripheral nerve stimulation (PNS) for the treatment of refractory chronic neuropathic pain. The 3-year study, funded under the NIH HEAL Initiative's CFDA 93.279 Drug Abuse and Addiction Research Programs, aims...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $294,505 to Molecular Theranostics LLC, a small disadvantaged business, to develop and commercialize a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer. The goal is to create a small peptide-based fluorescence probe that can be used to visualize and guide...

The University of Nebraska Medical Center (UNMC) was awarded a $437,331 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will support the development of a novel "optoelectronically active nerve adhesive" to accelerate peripheral nerve repair and regeneration. Specifically, the project aims to incorporate innovative...

This $638,718 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop and validate innovative techniques for selective, targeted neurostimulation of peripheral nerves. The key products and services to be delivered include: Testing the hypothesis that interferential current stimulation (I2CS) can selectively activate specific nerve...